title: Effect of bromocriptine on LH pulsatility in the polycystic ovary syndrome.
abstract: The effects were studied of bromocriptine, 10 mg daily for 1 year, on luteinizing hormone (LH) pulse characteristics in patients with classical polycystic ovarian syndrome (PCOS). All patients were hirsute, had been oligomenorrhoeic since menarche, had LH: FSH ratios of greater than 3:1, and either elevated serum testosterone (T) or dehydroepiandrosterone sulphate (DHAS) concentrations. In 10 subjects who completed the study menstrual frequency increased from an average of 3.6 to 8 per year but few of the cycles were ovulatory. Mean (SE) serum testosterone fell from 4.4 (0.5) nmol/l pretreatment to 2.8 (0.3) nmol/l (P less than 0.01) and DHAS from 7.9 (1.1) mumol/l to 5.4 (1.1) mumol/l (P less than 0.05). Serum delta 4 androstenedione and oestradiol did not change with bromocriptine treatment. Mean serum LH fell from 17.4 (2.4) IU/l to 11.2 (1.8) IU/l (P less than 0.03) after 12 months of bromocriptine. No pattern of LH pulsatility specific to PCOS was detected during 10 min sampling for an 8 h period prior to dopamine agonist treatment. LH interpeak interval (58 (5.2) min) and peak amplitude (156 (7.2%) of mean nadir) in untreated PCOS were similar to that of the mid-follicular stage of ovulatory cycles, and bromocriptine for 1 year did not alter these variables. We conclude that while bromocriptine reduces serum androgen levels and increases menstrual frequency it has no effect centrally to modify hypothalamic GnRH secretion. The reduction in LH levels by bromocriptine may be the result of diminished gonadotroph sensitivity to GnRH or reduced pituitary stores of LH available for release. Despite the return towards normal of various hormonal characteristics of PCOS, bromocriptine has little place in the management of this condition.
authors.affiliation: Department of Medicine, University of Birmingham, Harrow, Middlesex, UK.
authors.forename: A J
authors.initials: AJ
authors.lastname: Chapman
authors.forename: M D
authors.initials: MD
authors.lastname: Wilson
authors.forename: M
authors.initials: M
authors.lastname: Obhrai
authors.forename: R S
authors.initials: RS
authors.lastname: Sawers
authors.forename: S S
authors.initials: SS
authors.lastname: Lynch
authors.forename: J P
authors.initials: JP
authors.lastname: Royston
authors.forename: R N
authors.initials: RN
authors.lastname: Clayton
mesh_terms: D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000097:blood; D001971:Bromocriptine / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008598:Menstruation / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000728:Androgens; D001971:Bromocriptine; D004958:Estradiol; D007986:Luteinizing Hormone